Anti-TIGIT Demonstrates Potent Anti-Tumor Activity in Preclinical Models
WASHINGTON and REDWOOD CITY, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, presented data from multiple preclinical studies detailing the mechanism and anti-tumor activity of anti-TIGIT alone and in combination with checkpoint inhibitors at the AACR Annual Meeting 2017. These are the first data from OncoMed's anti-TIGIT program to be shared publicly. OncoMed plans to initiate a Phase 1a single-agent study of its anti-TIGIT antibody (OMP-313M32) in the first half of 2017.
"TIGIT is a highly desirable target in immuno-oncology with similarities in structure and function to PD1 and broad expression of its ligands on a wide variety of tumor tissues. We believe that by blocking TIGIT signaling our anti-TIGIT antibody may enable T-cell activation and facilitate a potent anti-tumor immune response, potentially halting the growth and recurrence of tumors," said Austin Gurney, Ph.D., OncoMed's Senior Vice President of Molecular and Cellular Biology and co-Chief Scientific Officer. "In multiple preclinical studies with anti-TIGIT antibodies we have observed immune activation and robust anti-tumor activity — both as a single agent and in combination with other cancer immunotherapeutics. Notably, the effect on inhibiting tumor growth persists upon re-challenging cured animals with re-injection of tumor cells, indicating that we are inducing a long-term immune memory response that we hope will translate into long-term clinical benefit. We look forward to advancing our anti-TIGIT antibody into the clinic in the first half of 2017."
Read More: http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1019847
OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
Comments are closed.